

Dolores Di Vizio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7079251/publications.pdf>

Version: 2024-02-01

53
papers

15,309
citations

116194

36
h-index

198040

52
g-index

56
all docs

56
docs citations

56
times ranked

21348
citing authors

#	ARTICLE	IF	CITATIONS
1	Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis. <i>Nature Communications</i> , 2022, 13, 669.	5.8	19
2	Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors. <i>Nature Communications</i> , 2022, 13, 1487.	5.8	17
3	Tumor Derived Extracellular Vesicles Drive T Cell Exhaustion in Tumor Microenvironment through Sphingosine Mediated Signaling and Impacting Immunotherapy Outcomes in Ovarian Cancer. <i>Advanced Science</i> , 2022, 9, e2104452.	5.6	20
4	An extracellular vesicle-based assay for noninvasive detection of metastases and monitoring prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e17004-e17004.	0.8	1
5	Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. <i>Nature Cell Biology</i> , 2021, 23, 87-98.	4.6	209
6	Nuclear size of circulating tumor cells in advanced prostate cancer to reveal a potential biomarker for clinical outcomes and androgen receptor indifference.. <i>Journal of Clinical Oncology</i> , 2021, 39, 167-167.	0.8	1
7	Genome-wide analysis of copy number alterations led to the characterisation of PDCD10 as oncogene in ovarian cancer. <i>Translational Oncology</i> , 2021, 14, 101013.	1.7	10
8	A morphological subset of circulating tumor cells in advanced prostate cancer reveals a potential biomarker for clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2021, 39, e17008-e17008.	0.8	0
9	Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4819-4832.	1.0	11
10	miR-1227 Targets SEC23A to Regulate the Shedding of Large Extracellular Vesicles. <i>Cancers</i> , 2021, 13, 5850.	1.7	2
11	A brief history of nearly EVâ€‘everything â€“ The rise and rise of extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12144.	5.5	150
12	Updating MISEV: Evolving the minimal requirements for studies of extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12182.	5.5	147
13	Large and small extracellular vesicles released by glioma cells <i>in vitro</i> and <i>in vivo</i> . <i>Journal of Extracellular Vesicles</i> , 2020, 9, 1689784.	5.5	57
14	Comprehensive palmitoylâ€‘proteomic analysis identifies distinct protein signatures for large and small cancerâ€‘derived extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2020, 9, 1764192.	5.5	37
15	Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 317.	3.5	82
16	Low-Background Acyl-Biotinyl Exchange Largely Eliminates the Coisolation of Non- <i>S</i> -Acylated Proteins and Enables Deep <i>S</i> -Acylproteomic Analysis. <i>Analytical Chemistry</i> , 2019, 91, 9858-9866.	3.2	32
17	Bio-Inspired NanoVilli Chips for Enhanced Capture of Tumor-Derived Extracellular Vesicles: Toward Non-Invasive Detection of Gene Alterations in Non-Small Cell Lung Cancer. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 13973-13983.	4.0	55
18	Protein Composition Reflects Extracellular Vesicle Heterogeneity. <i>Proteomics</i> , 2019, 19, e1800167.	1.3	86

#	ARTICLE	IF	CITATIONS
19	Size matters in nanoscale communication. <i>Nature Cell Biology</i> , 2018, 20, 228-230.	4.6	107
20	ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. <i>Nature Medicine</i> , 2018, 24, 1887-1898.	15.2	113
21	Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. <i>Journal of Extracellular Vesicles</i> , 2018, 7, 1535750.	5.5	6,961
22	Towards mechanisms and standardization in extracellular vesicle and extracellular RNA studies: results of a worldwide survey. <i>Journal of Extracellular Vesicles</i> , 2018, 7, 1535745.	5.5	45
23	PKM2 is not required for pancreatic ductal adenocarcinoma. <i>Cancer & Metabolism</i> , 2018, 6, 17.	2.4	26
24	Outer Membrane Vesicles Derived From <i>Escherichia coli</i> Regulate Neutrophil Migration by Induction of Endothelial IL-8. <i>Frontiers in Microbiology</i> , 2018, 9, 2268.	1.5	48
25	Emerin Deregulation Links Nuclear Shape Instability to Metastatic Potential. <i>Cancer Research</i> , 2018, 78, 6086-6097.	0.4	49
26	Large extracellular vesicles carry most of the tumour DNA circulating in prostate cancer patient plasma. <i>Journal of Extracellular Vesicles</i> , 2018, 7, 1505403.	5.5	286
27	Extracellular MicroRNA Signature of Human Helper T Cell Subsets in Health and Autoimmunity. <i>Journal of Biological Chemistry</i> , 2017, 292, 2903-2915.	1.6	63
28	MYC Mediates Large Oncosome-Induced Fibroblast Reprogramming in Prostate Cancer. <i>Cancer Research</i> , 2017, 77, 2306-2317.	0.4	119
29	A novel community driven software for functional enrichment analysis of extracellular vesicles data. <i>Journal of Extracellular Vesicles</i> , 2017, 6, 1321455.	5.5	314
30	Updating the MISEV minimal requirements for extracellular vesicle studies: building bridges to reproducibility. <i>Journal of Extracellular Vesicles</i> , 2017, 6, 1396823.	5.5	185
31	High-throughput sequencing of two populations of extracellular vesicles provides an mRNA signature that can be detected in the circulation of breast cancer patients. <i>RNA Biology</i> , 2017, 14, 305-316.	1.5	43
32	PKM2 is not required for colon cancer initiated by APC loss. <i>Cancer & Metabolism</i> , 2017, 5, 10.	2.4	28
33	Focus on Extracellular Vesicles: New Frontiers of Cell-to-Cell Communication in Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 175.	1.8	255
34	Oncosomes “large and small: what are they, where they came from?”. <i>Journal of Extracellular Vesicles</i> , 2016, 5, 33109.	5.5	133
35	Techniques used for the isolation and characterization of extracellular vesicles: results of a worldwide survey. <i>Journal of Extracellular Vesicles</i> , 2016, 5, 32945.	5.5	703
36	Induction of p53-independent apoptosis by ectopic expression of HOXA5 in human liposarcomas. <i>Scientific Reports</i> , 2015, 5, 12580.	1.6	27

#	ARTICLE	IF	CITATIONS
37	Large oncosomes contain distinct protein cargo and represent a separate functional class of tumor-derived extracellular vesicles. <i>Oncotarget</i> , 2015, 6, 11327-11341.	0.8	289
38	EVpedia: a community web portal for extracellular vesicles research. <i>Bioinformatics</i> , 2015, 31, 933-939.	1.8	317
39	Extracellular Vesicles in Cancer: Exosomes, Microvesicles and the Emerging Role of Large Oncosomes. <i>Seminars in Cell and Developmental Biology</i> , 2015, 40, 41-51.	2.3	675
40	Regulation of microtubule dynamics by DIAPH3 influences amoeboid tumor cell mechanics and sensitivity to taxanes. <i>Scientific Reports</i> , 2015, 5, 12136.	1.6	48
41	Enhanced shedding of extracellular vesicles from amoeboid prostate cancer cells. <i>Cancer Biology and Therapy</i> , 2014, 15, 409-418.	1.5	64
42	Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. <i>Journal of Extracellular Vesicles</i> , 2014, 3, 26913.	5.5	2,110
43	Trading in your spindles for blebs: the amoeboid tumor cell phenotype in prostate cancer. <i>Asian Journal of Andrology</i> , 2014, 16, 530.	0.8	12
44	A translational phase 2 study of cabozantinib in men with metastatic castration resistant prostate cancer with visceral metastases with characterization of circulating tumor cells and large oncosomes.. <i>Journal of Clinical Oncology</i> , 2014, 32, e16080-e16080.	0.8	0
45	Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression. <i>Journal of Pathology</i> , 2013, 231, 77-87.	2.1	93
46	Large Oncosomes in Human Prostate Cancer Tissues and in the Circulation of Mice with Metastatic Disease. <i>American Journal of Pathology</i> , 2012, 181, 1573-1584.	1.9	321
47	Proteome Scale Characterization of Human S-Acylated Proteins in Lipid Raft-enriched and Non-raft Membranes. <i>Molecular and Cellular Proteomics</i> , 2010, 9, 54-70.	2.5	252
48	Oncosome Formation in Prostate Cancer: Association with a Region of Frequent Chromosomal Deletion in Metastatic Disease. <i>Cancer Research</i> , 2009, 69, 5601-5609.	0.4	325
49	An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease spread and epithelial Akt activation. <i>Cell Cycle</i> , 2009, 8, 2420-2424.	1.3	141
50	Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase. <i>Cell Cycle</i> , 2008, 7, 2257-2267.	1.3	80
51	Cholesterol and Cholesterol-Rich Membranes in Prostate Cancer: An Update. <i>Tumori</i> , 2008, 94, 633-639.	0.6	60
52	Cholesterol and cholesterol-rich membranes in prostate cancer: an update. <i>Tumori</i> , 2008, 94, 633-9.	0.6	32
53	Caveolin-1 is required for the upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression. <i>Cancer Biology and Therapy</i> , 2007, 6, 1269-1274.	1.5	47